Intein-mediated rapid purification of recombinant human pituitary adenylate cyclase activating polypeptide

Acta Biochimica et Biophysica Sinica

Volumn 36, Issue 11, 2004, Pages 759-766

  Yu, Rong Jie ^a   Hong, An ^a   Dai, Yun ^a   Gao, Yuan ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Intein; Purification; Recombinant human pituitary adenylate cyclase activating peptide (rhPACAP)

Indexed keywords

CHITIN; CYCLIC AMP; DITHIOTHREITOL; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTEIN;

AFFINITY CHROMATOGRAPHY; AMINO TERMINAL SEQUENCE; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; PANCREAS CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN TARGETING;

ESCHERICHIA COLI;

EID: 15444373827     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: 10.1093/abbs/36.11.759     Document Type: Article

References (32)

1. Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: Neuroendocrine and endocrine interaction. Front Neuroendocrinol, 1995, 16: 53-88
2. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacol Rev, 2000, 52: 269-324
3. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn J Physiol, 1998, 48: 301-331
4. Li XL, Zhao XX. Pituitary adenylate cyclase activating polypeptide. Prog Biochem Biophys, 2001, 28: 140-144
5. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR et al. International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev, 1998, 50: 265-270
6. Waschek JA. Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev Neurosci, 2002, 24: 14-23
7. Li M, Funahashi H, Mbikay M, Shioda S, Arimura A. Pituitary adenylate cyclase activating polypeptide-mediated intracrine signaling in the testicular germ cells. Endocrine, 2004, 23: 59-75
8. Koves K, Kantor O, Molnar J, Heinzlmann A, Szabo E, Szabo F, Nemeskeri A et al. The role of PACAP in gonadotropic hormone secretion at hypothalamic and pituitary levels. J Mol Neurosci, 2003, 20: 141-152
9. Sato A, Wang PC, Ohgawara H. Effect of stimulators such as GLP-1, PACAP, and nicotinamide on glucose-stimulated insulin secretion from porcine pancreatic endocrine cells in long-term culture. Pancreas, 2002, 25: 86-93
10. Cazillis M, Gonzalez BJ, Billardon C, Lombet A, Fraichard A, Samarut J, Gressens P et al. VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells. Eur J Neurosci, 2004, 19: 798-808
11. Delgado M, Abad C, Martinez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP. PACAP in immunity and inflammation. Ann NY Acad Sci, 2003, 992: 141-157
12. Chang Q, Deng YP, Liu SH. Morphologic study on PACAP protecting vascular smooth muscle cell from damage by LDL. Progress of Anatomical Sciences, 1999, 5: 347-349
13. Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, de la Cruz F et al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal a potential therapy for type 2 diabetes. Diabetes, 2002, 51: 1453-1460
14. Guidone G, Muller D, Vogt K, Mukhopadhyay AK. Characterization of VIP and PACAP receptors in cultured rat penis corpus cavernosum smooth muscle cells and their interaction with guanylate cyclase-B receptors. Regul Pept, 2002, 10: 63-72
15. Dogrukol-Ak D, Tore F, Tuncel N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des, 2004, 10: 1325-1340
16. Pozo D. VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Med, 2003, 9: 211-217
17. Chong S, Mersha FB, Comb DG, Scott ME, Landry D, Vence LM, Perler FB et al. Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element. Gene, 1997, 192: 277-281
18. Yang LP, Kong XP, Yi XR. Analyzing peptides of low weights molecular with SDS-polyacrylamide gel electrophoresis, J Chinese Biotechnology, 1998, 18: 19-51
19. Yeo EJ, Briggs WT, Wagner C. Inhibition of glycine N-methyltransferase by 5-methyltetrahydrofolate pentaglutamate. J Biol Chem, 1999, 274: 37559-37564
20. Yung SL, de la Cruz F, Hamren S, Zhu J, Tsutsumi M, Bloom J W, Caudle M et al. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem, 2003, 278: 10273-10281
21. Kane PM, Yamashiro CT, Wolczyk DF, Neff N, Goebl M, Stevens TH. Protein splicing converts the yeast TFP1 gene product to the 69-kD subunit of the vacuolar H (+)-adenosine triphosphatase. Science, 1990, 250: 651-657
22. Perler FB, Davis EO, Dean GE, Gimble FS, Jack WE, Neff N, Noren CJ et al. Protein splicing elements: Inteins and exteins - a definition of cleavterms and recommended nomenclature. Nucleic Acids Res, 1994, 22: 1125-1127
23. Chong S, Shao Y, Paulus H, Benner J, Perler F B, Xu M Q. Protein splicing involving the Saccharomyces cerevisiae VMA intein: The steps in the splicing pathway, side reactions leading to protein cleavage, and establishment of an in vitro splicing system. J Biol Chem, 1996, 271: 22159-22168
24. Chong S, Montello GE, Zhang A, Cantor EJ, Liao W, Xu MQ, Benner J. Utilizing the C-terminal cleavage activity of a protein splicing element to purify recombinant proteins in a single chromatographic step. Nucleic Acids Res, 1998, 26: 5109-5115
25. Evans TC, Benner J, Xu MQ. The in vitro ligation of bacterially expressed proteins using an intein from Methanobacterium thermoautotrophicum. J Biol Chem, 1999, 274: 3923-3926
26. Southworth MW, Amaya K, Evans TC, Xu MQ, Perler FB. Purification of proteins fused to either the amino or carboxy terminus of the Mycobacterium xenopi gyrase intein. Biotechniques, 1999, 27: 110-120
27. Pisegna JR, Wank SA. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci USA, 1993, 90: 6345-6349
28. Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res, 2000, 60: 3105-3112
29. Schmidt WE, Seebeck J, Hocker M, Schwarzhoff R, Schafer H, Fornefeld H, Morys-Wortmann C et al. PACAP and VIP stimulate enzyme secretion in rat pancreatic acini via interaction with VIP/PACAP-2 receptors: Additive augmentation of CCK/carbachol-induced enzyme release. Pancreas, 1993, 8: 476-487
30. Zhao M, Sun LM, Jian RL. The role of pituitary adenylate cyclase activating polypeptide in the growth modulation of human pancreas cancinoma. Chin J Dig, 2001, 21: 86-89
31. Chen ZY, Chai YF, He C, Lu CL, Wu XF. Gene cloning and expression of PACAP and study of its biological activity. Prog Biochem Biophys, 2001, 28: 192-197
32. Langer I, Gregoire F, Nachtergael I, De Neef P, Vertongen P, Robberecht P. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency. Peptides, 2004, 25: 275-278